

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation
金斯瑞生物科技股份有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

OVERSEAS REGULATORY ANNOUNCEMENT
LEGEND BIOTECH ANNOUNCES RESULTS OF
ANNUAL GENERAL MEETING

This announcement is made by the board of directors (the “**Board**”) of Genscript Biotech Corporation (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) in relation to the voting results of the 2022 annual general meeting of Legend Biotech (the “**Results**”).

For details, please refer to the attached Results. The attached Results is the full Form 6-K as published on the SEC’s website available at <https://www.sec.gov/Archives/edgar/data/1801198/000115752322001325/0001157523-22-001325-index.htm>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By Order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 18 October 2022

As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

* For identification purposes only

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

Date of Report: October 17, 2022

Commission File Number: 001-39307

Legend Biotech Corporation
(Exact Name of Registrant as Specified in its Charter)

**2101 Cottontail Lane
Somerset, New Jersey 08873**
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(7):

On October 14, 2022, Legend Biotech Corporation (the “**Company**”) held its 2022 Annual General Meeting of Shareholders. The voting results are attached hereto as Exhibit 99.1.

This report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257609 and 333-257625) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

EXHIBITS

[Exhibit 99.1 — Voting Results of Annual General Meeting](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LEGEND BIOTECH CORPORATION

Date: October 17, 2022

By: /s/ Ying Huang
Name: Ying Huang, Ph.D.
Title: Chief Executive Officer

Voting Results of 2022 Annual General Meeting

At Legend Biotech Corporation's (the "Company") annual general meeting of shareholders held on October 14, 2022 (the "AGM"), the Company's shareholders:

- received the audited consolidated financial statements of the Company for the fiscal year ended December 31, 2021;
- ratified the appointment of Ernst & Young LLP as the Company's independent auditor for the fiscal year ending December 31, 2022;
- re-elected each of Dr. Patrick Casey, Mr. Philip Yau and Dr. Fangliang Zhang to serve as a Class II director for a three year term; and
- authorized each of the directors and officers of the Company to take any and every action that might be necessary to effect the forgoing resolutions as such director or officer, in his or her absolute discretion, thinks fit.

A total of approximately 324,090,586 ordinary shares, including those underlying ADSs, representing approximately 96.8% of the ordinary shares issued and outstanding as of September 13, 2022, the record date, were present in person or by proxy at the AGM. The results of the votes are as follows:

Resolutions	For		Against		Abstain	
	Votes	%	Votes	%	Votes	%
Reception of Audited Financial Statements	324,021,470	99.979%	1,912	0.001%	67,204	0.021%
Ratification of appointment of Ernst & Young LLP as Independent Auditor for Fiscal Year 2022	324,052,382	99.988%	6,026	0.002%	32,178	0.010%
Election of Directors						
Dr. Patrick Casey (Class II)	321,860,342	99.312%	2,194,242	0.677%	36,002	0.011%
Mr. Philip Yau (Class II)	319,090,836	98.457%	4,964,914	1.532%	34,836	0.011%
Dr. Fangliang Zhang (Class II)	323,676,232	99.884%	378,250	0.117%	36,104	0.011%
Authorization of Directors and Officers	323,789,904	99.919%	269,124	0.083%	31,558	0.010%

*Represents less than 0.001% of Votes.

Dr. Fangliang Zhang, Chairman of the Board of Directors, as the person designated by the Company, was granted a discretionary proxy by JPMorgan Chase Bank, N.A., the depository of the ADSs, pursuant to the Deposit Agreement governing the ADSs and the Voting Instruction Card mailed by the depository to the holders of the ADSs, to vote 14,463,776 ordinary shares underlying ADSs for which no voting instructions were given by the holders, and he exercised the discretionary proxy to vote in favor of each of the proposals submitted for shareholder approval at the AGM.